or Try an Advanced Search...

    Technical Analysis for CRDF - Cardiff Oncology, Inc.

    Grade Last Price % Change Price Change
    D 2.57 1.38% 0.04
    CRDF closed down 3.44 percent on Wednesday, November 20, 2024, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical CRDF trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 1.38%
    Narrow Range Bar Range Contraction 1.38%
    Wide Bands Range Expansion 1.38%
    Oversold Stochastic Weakness 1.38%
    MACD Bearish Centerline Cross Bearish -2.10%
    Doji - Bullish? Reversal -2.10%
    Wide Bands Range Expansion -2.10%
    Oversold Stochastic Weakness -2.10%
    NR7 Range Contraction -0.58%
    Narrow Range Bar Range Contraction -0.58%
    Older End-of-Day Signals for CRDF ...

       Recent Intraday Alerts

    Alert Time
    Up 2% about 1 hour ago
    60 Minute Opening Range Breakout about 2 hours ago
    Up 1% about 2 hours ago
    Down 2 % about 3 hours ago
    Fell Below Previous Day's Low about 4 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    CRDF Chart by TradingView
    Basic chart:

    Profile

    Cardiff Oncology, Inc. Description

    Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Medicine Cancer Clinical Medicine Pharmaceutical Solid Tumors Drugs Cancer Treatment Oncology Phosphates Acute Myeloid Leukemia Chemotherapy Lymphoma Prostate Cancer Antineoplastic Drugs Colorectal Cancer Leukemia Targeted Therapy Advanced Solid Tumors Solid Tumor Cancers Adenosine Metastatic Colorectal Cancer Resistant Prostate Cancer Metastatic Castration Resistant Prostate Cancer Nektar Therapeutics

    Is CRDF a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 19 Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
    Nov 9 Cardiff Oncology Third Quarter 2024 Earnings: Beats Expectations
    Nov 7 Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
    Nov 7 Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next
    Oct 30 Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
    Oct 24 3 US Penny Stocks With Market Caps Over $40M
    Oct 4 Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
    Aug 12 Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point
    Aug 10 Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
    Aug 8 Cardiff Oncology GAAP EPS of -$0.26 misses by $0.01, revenue of $0.16M beats by $0.1M
    See more CRDF news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.42
    52 Week Low 1.1501
    Average Volume 807,719
    200-Day Moving Average 3.09
    50-Day Moving Average 2.84
    20-Day Moving Average 3.11
    10-Day Moving Average 2.99
    Average True Range 0.32
    RSI (14) 40.48
    ADX 29.56
    +DI 18.35
    -DI 23.17
    Chandelier Exit (Long, 3 ATRs) 3.41
    Chandelier Exit (Short, 3 ATRs) 3.48
    Upper Bollinger Bands 3.98
    Lower Bollinger Band 2.24
    Percent B (%b) 0.17
    BandWidth 55.91
    MACD Line -0.05
    MACD Signal Line 0.07
    MACD Histogram -0.1255
    Fundamentals Value
    Market Cap 113.03 Million
    Num Shares 44.7 Million
    EPS -0.92
    Price-to-Earnings (P/E) Ratio -2.75
    Price-to-Sales 174.60
    Price-to-Book 1.04
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.76
    Resistance 3 (R3) 2.77 2.71 2.72
    Resistance 2 (R2) 2.71 2.66 2.71 2.70
    Resistance 1 (R1) 2.62 2.62 2.59 2.61 2.69
    Pivot Point 2.56 2.56 2.55 2.56 2.56
    Support 1 (S1) 2.47 2.51 2.44 2.46 2.37
    Support 2 (S2) 2.41 2.47 2.41 2.36
    Support 3 (S3) 2.32 2.41 2.34
    Support 4 (S4) 2.31